Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2005
Event: Confirmation of patent grant from the United States Patent and Trademark Office for the OLpur(TM) H2H(TM) product.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the receipt of confirmation from the USPTO that Nephros, Inc. will be granted a patent for its OLpur(TM) H2H(TM) product. This represents a significant milestone in the company's intellectual property portfolio.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) announcing the patent confirmation.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in this report shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that Section. No specific financial risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the patent scope and commercial implications.
- Confirm the specific patent number and filing date with the USPTO database.
- Review subsequent filings (10-Q or 10-K) for financial impact related to the commercialization of the OLpur(TM) H2H(TM) product.